Principles for Responsible Clinical Trial Data Sharing

The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information. In July 2013, PhRMA joined with the European Federation of Pharmaceutical Industries and Associations (EFPIA) in adopting joint Principles for Responsible Clinical Trial Data Sharing.

PhRMA Principles for Responsible Clinical Trial Data Sharing

Personalized Cancer Medicines Helping Patients Live Longer, Healthier Lives

07.01.13 | By

CBS News featured a segment over the weekend on the value of new cancer treatments and how precision medicine, also known as personalized medicine, is changing the way patients receive care.

Medicines in Development: Heart Disease and Stroke Overview

Medicines in Development: Heart Disease and Stroke

Research in Indiana

Innovative Oncology Medicines Have Led to Impressive Gains in Patient Survivorship

WASHINGTON, D.C. (May 31, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement highlighting the value of innovative cancer medicines for patients, the economy and the U.S. health care system:

A Day In The Life

PhRMA Clinical Trial Principles Strengthen Authorship Standards

Washington, D.C. (September 18, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding efforts to enhance transparency in clinical research:

PhRMA Statement on 2013 Special 301 Report

WASHINGTON, D.C. (May 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) International Vice President Jay Taylor issued the following statement today:

Pages

Subscribe to RSS - Innovation